Company / R&D Expense
HealthEquity R&D Expense History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$218.8M
FY2026
5-year range
$77.6M / $262.5M
FY2022-FY2026
Trend
-16.6%
vs FY2025
Sector context
#34 of 110
Health Care
What the data says
At $219M, HealthEquity's r&d expense ranks #34 of 110 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $27M in FY2017 to $263M in FY2025.
Based on SEC 10-K filings.
$219M in FY2026 with a 5-year CAGR of +44.2%.
Declined from $240M to $219M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +0.0%
- 5-Year CAGR
- +44.2%
- 10-Year CAGR
- -
Sector benchmark
#34 of 110 in Health CareTop 31% of 110This company $218.8M Sector average $298.2M
▼
-26.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +44.2%, indicating consistent growth.
- In FY2026, r&d expense decreased 16.6% year-over-year.
- Ranks #34 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2025.
Company context
Key Data Points
- Altman Z-Score 1.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $218.8M | -16.6% |
| FY2025 | $262.5M | +9.6% |
| FY2024 | $239.5M | +9.5% |
| FY2023 | $218.8M | +182.1% |
| FY2022 | $77.6M | +121.3% |
| FY2021 | $35.1M | -71.9% |
| FY2020 | $124.8M | +60.9% |
| FY2019 | $77.6M | +121.3% |
| FY2018 | $35.1M | +28.0% |
| FY2017 | $27.4M | +22.4% |
As of FY2026 · SEC 10-K · Updated Jun 30, 2026